Arrowhead Pharmaceuticals, Inc. (ARWR) Balance Sheet

The balance sheet shows extreme quarter-to-quarter swings, with total assets ranging from $883.8M in 2024Q3 to $2.3B in 2026Q2. Equity dropped to $52.6M in 2025Q1, indicating a period of heavy losses, but rebounded to $614.0M by 2026Q2, likely due to a financing event. This volatility suggests the company's financial position is heavily dependent on external capital and milestone receipts, not organic profitability.

The debt profile is dominated by convertible notes, as evidenced by the sharp increase in total debt to $1.4B in 2026Q2, which coincided with a rise in cash to $188.5M. The D/E ratio of 15.55 in 2025Q1 indicates that the company was highly leveraged relative to its equity base, but the subsequent equity raise and debt repayment reduced leverage to 1.85 by 2026Q3. This suggests that debt is used strategically to fund operations and bridge to milestones, but the high leverage in certain quarters poses refinancing risk if milestones are delayed.

The company's asset base is primarily composed of cash and short-term investments, with PPE net growing modestly to $429.0M, suggesting investment in manufacturing or lab facilities. Goodwill is negligible at $5.6M, implying that growth has been organic rather than through acquisitions. The low goodwill and stable PPE indicate that the asset base is not at risk of impairment, but the increasing PPE suggests a shift towards more capital-intensive operations, which could increase fixed costs.

The equity base is highly volatile, with retained earnings consistently negative and reaching -$1.9B by 2026Q3. The fluctuations in equity, from $52.6M to $683.3M, are driven by financing activities rather than retained earnings, suggesting that shareholder value is being diluted over time. Stock-based compensation, as noted in the income statement analysis, adds to dilution without cash outflow, further eroding equity quality.

The current ratio is consistently above 3, indicating adequate short-term liquidity, but the absolute cash position has declined significantly to $54.8M in 2026Q3. This cash level may only cover a few quarters of operating expenses, given the R&D burn of ~$200M per quarter. The high current ratio is flattered by the low level of current liabilities, which may not fully reflect upcoming obligations. Investors should monitor the cash runway closely, especially if milestone payments are delayed.

Deferred revenue appeared only in 2025Q3 and grew to $165.8M by 2026Q1, reflecting upfront payments from licensing agreements that are recognized over time. The decline to $126.3M in 2026Q3 suggests that some revenue was recognized, but the volatility indicates that future revenue visibility is limited. The lack of deferred revenue in earlier quarters implies that the company's revenue stream is not recurring, making forward estimates uncertain.